FGFR1 and hepatocellular carcinoma: Diarrhea is also commonly reported (~40% of cases) in lenvatinib treatment, the first‐line treatment for HCC, which inhibits FGFR1–4 amongst other receptors (e.g., vascular endothelial growth factor, platelet‐derived growth factor).46, 47, 48